1057676-76-2

Basic information

• Product Name: 6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]nicotinonitrile
• Synonyms: 6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]nicotinonitrile
• CAS NO: 1057676-76-2
• Molecular Weight: 406.49
• Mol File: 1057676-76-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]nicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]nicotinonitrile(1057676-76-2)
• EPA Substance Registry System: 6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]nicotinonitrile(1057676-76-2)

Safety Data

• Hazardous Substances Data: 1057676-76-2(Hazardous Substances Data)

Upstream product

• 33252-28-7 6-chloronicotinonitrile 
• 683274-61-5 tert-butyl 4-(5-cyanopyridine-2-yl)piperazine-1-carboxylate 
• 40848-53-1 1-benzyl-4-chlorophthalazine 
• 149554-29-0 6-piperazin-1-yl-nicotinonitrile 

Downstream Products

• 1057679-83-0 N-{6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]pyridin-3-ylmethyl}acetamide 
• 1057677-39-0 1-{6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]pyridin-3-yl}-1-methylethylamine 
• 1057679-84-1 {6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]pyridin-3-yl}methylamine 

Relevant articles and documents

Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1- yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis

Sphingosine 1-phosphate (S1P) lyase has recently been implicated as a therapeutic target for the treatment of multiple sclerosis (MS), based on studies in a genetic mouse model. Potent active site directed inhibitors of the enzyme are not known so far. Here we describe the discovery of (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitrile 5 in a high-throughput screen using a biochemical assay, and its further optimization. This class of compounds was found to inhibit catalytic activity of S1PL by binding to the active site of the enzyme, as seen in the cocrystal structure of derivative 31 with the homodimeric human S1P lyase. 31 induces profound reduction of peripheral T cell numbers after oral dosage and confers pronounced protection in a rat model of multiple sclerosis. In conclusion, this novel class of direct S1P lyase inhibitors provides excellent tools to further explore the therapeutic potential of T cell-targeted therapies in multiple sclerosis and other autoimmune and inflammatory diseases.

ORGANIC COMPOUNDS AND THEIR USES

The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula (I).